WASP confers selective advantage for specific hematopoietic cell populations and serves a unique role in marginal zone B-cell homeostasis and function.
暂无分享,去创建一个
L. Notarangelo | H. Ochs | S. Snapper | F. Wermeling | L. Westerberg | M. Karlsson | M. A. de la Fuente
[1] M. Roncarolo,et al. Development of lentiviral gene therapy for Wiskott Aldrich syndrome , 2008, Expert opinion on biological therapy.
[2] L. Notarangelo,et al. The Wiskott-Aldrich syndrome. , 2006, The Journal of allergy and clinical immunology.
[3] S. Burns,et al. Impaired T-cell priming in vivo resulting from dysfunction of WASp-deficient dendritic cells. , 2007, Blood.
[4] M. Carroll,et al. Natural IgM-mediated innate autoimmunity: a new target for early intervention of ischemia–reperfusion injury , 2007, Expert opinion on biological therapy.
[5] A. Scheynius,et al. Class A scavenger receptors regulate tolerance against apoptotic cells, and autoantibodies against these receptors are predictive of systemic lupus , 2007, The Journal of experimental medicine.
[6] R. Xavier,et al. Wiskott–Aldrich syndrome protein (WASP) and N-WASP are critical for T cell development , 2007, Proceedings of the National Academy of Sciences.
[7] F. Candotti,et al. The Phenomenon of Spontaneous Genetic Reversions in the Wiskott-Aldrich Syndrome: A Report of the Workshop of the ESID Genetics Working Party at the XIIth Meeting of the European Society for Immunodeficiencies (ESID). Budapest, Hungary October 4–7, 2006 , 2007, Journal of Clinical Immunology.
[8] R. Siegel,et al. Impaired in vitro regulatory T cell function associated with Wiskott-Aldrich syndrome. , 2007, Clinical immunology.
[9] Albert Bendelac,et al. The biology of NKT cells. , 2007, Annual review of immunology.
[10] O. Danos,et al. Lentiviral vectors targeting WASp expression to hematopoietic cells, efficiently transduce and correct cells from WAS patients , 2007, Gene Therapy.
[11] S. Snapper,et al. The Wiskott-Aldrich syndrome protein is required for the function of CD4+CD25+Foxp3+ regulatory T cells , 2007, The Journal of experimental medicine.
[12] L. Notarangelo,et al. WASP regulates suppressor activity of human and murine CD4+CD25+FOXP3+ natural regulatory T cells , 2007, The Journal of experimental medicine.
[13] S. Ziegler,et al. Wiskott-Aldrich syndrome protein is required for regulatory T cell homeostasis. , 2007, The Journal of clinical investigation.
[14] S. Giliani,et al. Stem cell transplantation for the Wiskott–Aldrich syndrome: a single-center experience confirms efficacy of matched unrelated donor transplantation , 2006, Bone Marrow Transplantation.
[15] U. Pannicke,et al. Retroviral WASP gene transfer into human hematopoietic stem cells reconstitutes the actin cytoskeleton in myeloid progeny cells differentiated in vitro. , 2006, Experimental hematology.
[16] R. Mebius,et al. Structure and function of the spleen , 2005, Nature Reviews Immunology.
[17] F. Alt,et al. WASP deficiency leads to global defects of directed leukocyte migration in vitro and in vivo , 2005, Journal of leukocyte biology.
[18] Samantha J. Hardy,et al. Impaired dendritic-cell homing in vivo in the absence of Wiskott-Aldrich syndrome protein. , 2005, Blood.
[19] Samantha J. Hardy,et al. Wiskott-Aldrich syndrome protein deficiency leads to reduced B-cell adhesion, migration, and homing, and a delayed humoral immune response. , 2005, Blood.
[20] E. Remold-O’Donnell,et al. Phenotypic perturbation of B cells in the Wiskott–Aldrich syndrome , 2005, Clinical and experimental immunology.
[21] W. Vainchenker,et al. Mechanisms of WASp-mediated hematologic and immunologic disease. , 2004, Blood.
[22] F. Candotti,et al. Multiple patients with revertant mosaicism in a single Wiskott-Aldrich syndrome family. , 2004, Blood.
[23] R. Proia,et al. Sphingosine 1-phosphate receptor 1 promotes B cell localization in the splenic marginal zone , 2004, Nature Immunology.
[24] R. V. van Lier,et al. B Cells Are Crucial for Both Development and Maintenance of the Splenic Marginal Zone1 , 2004, The Journal of Immunology.
[25] J. Kearney,et al. Development and selection of marginal zone B cells , 2004, Immunological reviews.
[26] F. Candotti,et al. Differential contribution of Wiskott-Aldrich syndrome protein to selective advantage in T- and B-cell lineages. , 2004, Blood.
[27] P. Doherty,et al. Defects in T-cell-mediated immunity to influenza virus in murine Wiskott-Aldrich syndrome are corrected by oncoretroviral vector-mediated gene transfer into repopulating hematopoietic cells. , 2003, Blood.
[28] E. Haddad,et al. A defect in hematopoietic stem cell migration explains the nonrandom X-chromosome inactivation in carriers of Wiskott-Aldrich syndrome. , 2003, Blood.
[29] R. Steinman,et al. Macrophages Control the Retention and Trafficking of B Lymphocytes in the Splenic Marginal Zone , 2003, The Journal of experimental medicine.
[30] S. Aizawa,et al. Notch2 is preferentially expressed in mature B cells and indispensable for marginal zone B lineage development. , 2003, Immunity.
[31] F. Alt,et al. Gene therapy for Wiskott-Aldrich syndrome: rescue of T-cell signaling and amelioration of colitis upon transplantation of retrovirally transduced hematopoietic stem cells in mice. , 2003, Blood.
[32] Yasuhiko Ito,et al. Mixed chimera status of 12 patients with Wiskott-Aldrich syndrome (WAS) after hematopoietic stem cell transplantation: evaluation by flow cytometric analysis of intracellular WAS protein expression. , 2002, Blood.
[33] J. Cyster,et al. Integrin-Mediated Long-Term B Cell Retention in the Splenic Marginal Zone , 2002, Science.
[34] F. Candotti,et al. Retrovirus-mediated WASP gene transfer corrects Wiskott-Aldrich syndrome T-cell dysfunction. , 2002, Human gene therapy.
[35] Yann Leverrier,et al. Cutting Edge: The Wiskott-Aldrich Syndrome Protein Is Required for Efficient Phagocytosis of Apoptotic Cells1 , 2001, The Journal of Immunology.
[36] J. V. Stone,et al. Impact of donor type on outcome of bone marrow transplantation for Wiskott-Aldrich syndrome: collaborative study of the International Bone Marrow Transplant Registry and the National Marrow Donor Program. , 2001, Blood.
[37] W. Vermi,et al. The spleen in the Wiskott-Aldrich syndrome: histopathologic abnormalities of the white pulp correlate with the clinical phenotype of the disease. , 1999, The American journal of surgical pathology.
[38] R. Badolato,et al. Monocytes from Wiskott-Aldrich patients display reduced chemotaxis and lack of cell polarization in response to monocyte chemoattractant protein-1 and formyl-methionyl-leucyl-phenylalanine. , 1998, Journal of immunology.
[39] Philip R. Cohen,et al. Wiskott-Aldrich syndrome protein-deficient mice reveal a role for WASP in T but not B cell activation. , 1998, Immunity.
[40] Dunn,et al. Chemotaxis of macrophages is abolished in the Wiskott‐Aldrich syndrome , 1998, British journal of haematology.
[41] S. Kanner,et al. Wiskott-Aldrich syndrome/X-linked thrombocytopenia: WASP gene mutations, protein expression, and phenotype. , 1997, Blood.
[42] F. Alt,et al. Defective B cell development and function in Btk-deficient mice. , 1995, Immunity.
[43] F. Rosen,et al. Nonrandom inactivation of the X chromosome in early lineage hematopoietic cells in carriers of Wiskott-Aldrich syndrome. , 1995, Blood.
[44] K. Sullivan,et al. A multiinstitutional survey of the Wiskott-Aldrich syndrome. , 1994, The Journal of pediatrics.
[45] D J Rawlings,et al. Mutation of unique region of Bruton's tyrosine kinase in immunodeficient XID mice. , 1993, Science.
[46] M. Zachariah,et al. Follicular shuttling of marginal zone B cells facilitates antigen transport , 2008, Nature Immunology.
[47] A. Fischer,et al. Long-term outcome following hematopoietic stem-cell transplantation in Wiskott-Aldrich syndrome: collaborative study of the European Society for Immunodeficiencies and European Group for Blood and Marrow Transplantation. , 2008, Blood.
[48] S. Pillai,et al. Marginal zone B cells. , 2005, Annual review of immunology.
[49] R. Hardy,et al. B cell development pathways. , 2001, Annual review of immunology.